{
  "articles": [
    {
      "path": "about.html",
      "title": "Data analysis",
      "description": "Cochrane intervention study",
      "author": [],
      "contents": "\nThis is an website for internal use among the researchers on this study. The data are not currently provided in the codebase because I need to check with the PI about data sharing.\n\n\n\n",
      "last_modified": "2021-04-07T20:14:15+01:00"
    },
    {
      "path": "covidence.html",
      "title": "Covidence",
      "description": "For checking with Hollie and Gav.\n",
      "author": [],
      "date": "`r Sys.Date()`",
      "contents": "\n\nContents\nin this document\nmodel definition\nQA for model\nkeywords\n\nprotocol notes\nbackground\ndescription\n\n\n\n\n\n\nin this document\nmodel notes from protocol\nQA for model\nmodel definition\nThese all have different objectives, but are overlapping.\nmodel definition\nQA for model\nkeywords\n\n\n\n\nhtml {\n  font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Helvetica Neue', 'Fira Sans', 'Droid Sans', Arial, sans-serif;\n}\n\n#scunscpyeb .gt_table {\n  display: table;\n  border-collapse: collapse;\n  margin-left: auto;\n  margin-right: auto;\n  color: #333333;\n  font-size: 16px;\n  font-weight: normal;\n  font-style: normal;\n  background-color: aliceblue;\n  width: auto;\n  border-top-style: solid;\n  border-top-width: 2px;\n  border-top-color: #A8A8A8;\n  border-right-style: none;\n  border-right-width: 2px;\n  border-right-color: #D3D3D3;\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #A8A8A8;\n  border-left-style: none;\n  border-left-width: 2px;\n  border-left-color: #D3D3D3;\n}\n\n#scunscpyeb .gt_heading {\n  background-color: aliceblue;\n  text-align: center;\n  border-bottom-color: aliceblue;\n  border-left-style: none;\n  border-left-width: 1px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 1px;\n  border-right-color: #D3D3D3;\n}\n\n#scunscpyeb .gt_title {\n  color: #333333;\n  font-size: 125%;\n  font-weight: initial;\n  padding-top: 4px;\n  padding-bottom: 4px;\n  border-bottom-color: aliceblue;\n  border-bottom-width: 0;\n}\n\n#scunscpyeb .gt_subtitle {\n  color: #333333;\n  font-size: 85%;\n  font-weight: initial;\n  padding-top: 0;\n  padding-bottom: 4px;\n  border-top-color: aliceblue;\n  border-top-width: 0;\n}\n\n#scunscpyeb .gt_bottom_border {\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n}\n\n#scunscpyeb .gt_col_headings {\n  border-top-style: solid;\n  border-top-width: 2px;\n  border-top-color: #D3D3D3;\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n  border-left-style: none;\n  border-left-width: 1px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 1px;\n  border-right-color: #D3D3D3;\n}\n\n#scunscpyeb .gt_col_heading {\n  color: #333333;\n  background-color: aliceblue;\n  font-size: 100%;\n  font-weight: normal;\n  text-transform: inherit;\n  border-left-style: none;\n  border-left-width: 1px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 1px;\n  border-right-color: #D3D3D3;\n  vertical-align: bottom;\n  padding-top: 5px;\n  padding-bottom: 6px;\n  padding-left: 5px;\n  padding-right: 5px;\n  overflow-x: hidden;\n}\n\n#scunscpyeb .gt_column_spanner_outer {\n  color: #333333;\n  background-color: aliceblue;\n  font-size: 100%;\n  font-weight: normal;\n  text-transform: inherit;\n  padding-top: 0;\n  padding-bottom: 0;\n  padding-left: 4px;\n  padding-right: 4px;\n}\n\n#scunscpyeb .gt_column_spanner_outer:first-child {\n  padding-left: 0;\n}\n\n#scunscpyeb .gt_column_spanner_outer:last-child {\n  padding-right: 0;\n}\n\n#scunscpyeb .gt_column_spanner {\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n  vertical-align: bottom;\n  padding-top: 5px;\n  padding-bottom: 6px;\n  overflow-x: hidden;\n  display: inline-block;\n  width: 100%;\n}\n\n#scunscpyeb .gt_group_heading {\n  padding: 8px;\n  color: #FFFFFF;\n  background-color: steelblue;\n  font-size: 100%;\n  font-weight: initial;\n  text-transform: inherit;\n  border-top-style: solid;\n  border-top-width: 2px;\n  border-top-color: #D3D3D3;\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n  border-left-style: none;\n  border-left-width: 1px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 1px;\n  border-right-color: #D3D3D3;\n  vertical-align: middle;\n}\n\n#scunscpyeb .gt_empty_group_heading {\n  padding: 0.5px;\n  color: #FFFFFF;\n  background-color: steelblue;\n  font-size: 100%;\n  font-weight: initial;\n  border-top-style: solid;\n  border-top-width: 2px;\n  border-top-color: #D3D3D3;\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n  vertical-align: middle;\n}\n\n#scunscpyeb .gt_from_md > :first-child {\n  margin-top: 0;\n}\n\n#scunscpyeb .gt_from_md > :last-child {\n  margin-bottom: 0;\n}\n\n#scunscpyeb .gt_row {\n  padding-top: 8px;\n  padding-bottom: 8px;\n  padding-left: 5px;\n  padding-right: 5px;\n  margin: 10px;\n  border-top-style: solid;\n  border-top-width: 1px;\n  border-top-color: #D3D3D3;\n  border-left-style: none;\n  border-left-width: 1px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 1px;\n  border-right-color: #D3D3D3;\n  vertical-align: middle;\n  overflow-x: hidden;\n}\n\n#scunscpyeb .gt_stub {\n  color: #333333;\n  background-color: aliceblue;\n  font-size: 100%;\n  font-weight: initial;\n  text-transform: inherit;\n  border-right-style: solid;\n  border-right-width: 2px;\n  border-right-color: #D3D3D3;\n  padding-left: 12px;\n}\n\n#scunscpyeb .gt_summary_row {\n  color: #333333;\n  background-color: aliceblue;\n  text-transform: inherit;\n  padding-top: 8px;\n  padding-bottom: 8px;\n  padding-left: 5px;\n  padding-right: 5px;\n}\n\n#scunscpyeb .gt_first_summary_row {\n  padding-top: 8px;\n  padding-bottom: 8px;\n  padding-left: 5px;\n  padding-right: 5px;\n  border-top-style: solid;\n  border-top-width: 2px;\n  border-top-color: #D3D3D3;\n}\n\n#scunscpyeb .gt_grand_summary_row {\n  color: #333333;\n  background-color: aliceblue;\n  text-transform: inherit;\n  padding-top: 8px;\n  padding-bottom: 8px;\n  padding-left: 5px;\n  padding-right: 5px;\n}\n\n#scunscpyeb .gt_first_grand_summary_row {\n  padding-top: 8px;\n  padding-bottom: 8px;\n  padding-left: 5px;\n  padding-right: 5px;\n  border-top-style: double;\n  border-top-width: 6px;\n  border-top-color: #D3D3D3;\n}\n\n#scunscpyeb .gt_striped {\n  background-color: rgba(128, 128, 128, 0.05);\n}\n\n#scunscpyeb .gt_table_body {\n  border-top-style: solid;\n  border-top-width: 2px;\n  border-top-color: #D3D3D3;\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n}\n\n#scunscpyeb .gt_footnotes {\n  color: #333333;\n  background-color: aliceblue;\n  border-bottom-style: none;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n  border-left-style: none;\n  border-left-width: 2px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 2px;\n  border-right-color: #D3D3D3;\n}\n\n#scunscpyeb .gt_footnote {\n  margin: 0px;\n  font-size: 90%;\n  padding: 4px;\n}\n\n#scunscpyeb .gt_sourcenotes {\n  color: #333333;\n  background-color: aliceblue;\n  border-bottom-style: none;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n  border-left-style: none;\n  border-left-width: 2px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 2px;\n  border-right-color: #D3D3D3;\n}\n\n#scunscpyeb .gt_sourcenote {\n  font-size: 90%;\n  padding: 4px;\n}\n\n#scunscpyeb .gt_left {\n  text-align: left;\n}\n\n#scunscpyeb .gt_center {\n  text-align: center;\n}\n\n#scunscpyeb .gt_right {\n  text-align: right;\n  font-variant-numeric: tabular-nums;\n}\n\n#scunscpyeb .gt_font_normal {\n  font-weight: normal;\n}\n\n#scunscpyeb .gt_font_bold {\n  font-weight: bold;\n}\n\n#scunscpyeb .gt_font_italic {\n  font-style: italic;\n}\n\n#scunscpyeb .gt_super {\n  font-size: 65%;\n}\n\n#scunscpyeb .gt_footnote_marks {\n  font-style: italic;\n  font-size: 65%;\n}\nInclusion criteria\n    Columns including or excluding these words are extracted from the Covid export\n    \n      inclusion_criterion\n    substantial pain\n    pain + 50%\n      include\n    moderate pain\n    pain + 30%\n      include\n    mood\n    Mental health\n      include\n    Depression\n      include\n    Mood\n      include\n    Anxiety\n      include\n    Mental component\n      include\n    Psychosocial\n      include\n    Sadness\n      include\n    Well-being\n      include\n    adverse\n    Adverse drug reaction\n      include\n    Adverse events\n      include\n    Serious adverse events\n      include\n    sleep\n    Sleep\n      include\n    Insomnia\n      include\n    pgic\n    Global impression\n      include\n    Global judgement\n      include\n    Illness severity\n      include\n    Global Clinical Improvement\n      include\n    PGI-I\n      include\n    PGII-I\n      include\n    PGIC\n      include\n    CGI-S\n      include\n    Patient Global Assessment\n      include\n    Patient’s Global Evaluation\n      include\n    physical function\n    Disability\n      include\n    Function\n      include\n    Physical component\n      include\n    Physical function\n      include\n    Sickness Impact Profile\n      include\n    Physical functioning\n      include\n    qol\n    Quality of Life\n      include\n    QoL – EQ-5D\n      include\n    SF-36 Total Score\n      include\n    pain\n    Pain intensity\n      include\n    Pain severity\n      include\n    Pain unpleasantness\n      include\n    Somatisation\n      include\n    pain catastrophising\n      exclude\n    pain interference\n      exclude\n    50%\n      exclude\n    30%\n      exclude\n    \n\nprotocol notes\nbackground\nWe want to assess the comparative efficacy of antidepressants for adults with chronic pain.\ndescription\nchronic pain := > 3 months\nprimary pain := chronic pain as disease, e.g. lower back pain\nsecondary pian := pain with a specific cause, e.g., osteoarthritis\nassessed by self report\naffects 1/5 of adults in the world\naffects qol, mood, sleep, physical function, depression\n\n\n\n",
      "last_modified": "2021-04-07T20:20:18+01:00"
    },
    {
      "path": "index.html",
      "title": "Cochrane intervention analysis",
      "description": "Key information about the analysis on the use of antidepressants to treat chronic pain\n",
      "author": [],
      "contents": "\n\n\n\n\n\n\n\n\n\nAs of Wednesday 7 April 2021, the analysis currently includes 162 out of an expected 178 studies.\n\n\n\nanalysis pipeline\n\n\n{\"x\":{\"nodes\":{\"name\":[\"obs_numeric\",\"network_binom\",\"outcomes\",\"network_smd\",\"obs_measures\",\"obs_timepoints\",\"models\",\"model_smd\",\"obs_smd\",\"hpp_dat\",\"keywords\",\"data_update_date\",\"outcomes_of_interest\",\"obs_meta\",\"raw_hpp_dat\",\"raw_dat_path\",\"model_binom\",\"obs_wide_by_measures\",\"raw_names\",\"obs_postint\",\"obs\",\"obs_binom\"],\"type\":[\"pattern\",\"pattern\",\"stem\",\"pattern\",\"pattern\",\"pattern\",\"stem\",\"pattern\",\"stem\",\"stem\",\"stem\",\"stem\",\"stem\",\"pattern\",\"stem\",\"stem\",\"pattern\",\"pattern\",\"stem\",\"pattern\",\"pattern\",\"stem\"],\"status\":[\"none\",\"none\",\"none\",\"none\",\"none\",\"none\",\"none\",\"none\",\"none\",\"none\",\"none\",\"none\",\"none\",\"none\",\"none\",\"none\",\"none\",\"none\",\"none\",\"none\",\"none\",\"none\"],\"seconds\":[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null],\"bytes\":[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null],\"branches\":[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null],\"id\":[\"obs_numeric\",\"network_binom\",\"outcomes\",\"network_smd\",\"obs_measures\",\"obs_timepoints\",\"models\",\"model_smd\",\"obs_smd\",\"hpp_dat\",\"keywords\",\"data_update_date\",\"outcomes_of_interest\",\"obs_meta\",\"raw_hpp_dat\",\"raw_dat_path\",\"model_binom\",\"obs_wide_by_measures\",\"raw_names\",\"obs_postint\",\"obs\",\"obs_binom\"],\"label\":[\"obs_numeric\",\"network_binom\",\"outcomes\",\"network_smd\",\"obs_measures\",\"obs_timepoints\",\"models\",\"model_smd\",\"obs_smd\",\"hpp_dat\",\"keywords\",\"data_update_date\",\"outcomes_of_interest\",\"obs_meta\",\"raw_hpp_dat\",\"raw_dat_path\",\"model_binom\",\"obs_wide_by_measures\",\"raw_names\",\"obs_postint\",\"obs\",\"obs_binom\"],\"level\":[9,12,3,12,5,7,14,13,11,3,1,2,2,8,2,1,13,6,3,10,4,11],\"color\":[\"#94a4ac\",\"#94a4ac\",\"#94a4ac\",\"#94a4ac\",\"#94a4ac\",\"#94a4ac\",\"#94a4ac\",\"#94a4ac\",\"#94a4ac\",\"#94a4ac\",\"#94a4ac\",\"#94a4ac\",\"#94a4ac\",\"#94a4ac\",\"#94a4ac\",\"#94a4ac\",\"#94a4ac\",\"#94a4ac\",\"#94a4ac\",\"#94a4ac\",\"#94a4ac\",\"#94a4ac\"],\"shape\":[\"square\",\"square\",\"dot\",\"square\",\"square\",\"square\",\"dot\",\"square\",\"dot\",\"dot\",\"dot\",\"dot\",\"dot\",\"square\",\"dot\",\"dot\",\"square\",\"square\",\"dot\",\"square\",\"square\",\"dot\"]},\"edges\":{\"from\":[\"obs_meta\",\"obs_binom\",\"outcomes_of_interest\",\"obs_smd\",\"obs\",\"obs_wide_by_measures\",\"model_binom\",\"model_smd\",\"network_smd\",\"obs_postint\",\"outcomes\",\"raw_hpp_dat\",\"raw_dat_path\",\"keywords\",\"hpp_dat\",\"obs_timepoints\",\"raw_dat_path\",\"network_binom\",\"obs_measures\",\"raw_hpp_dat\",\"obs_numeric\",\"outcomes_of_interest\",\"hpp_dat\",\"keywords\",\"outcomes_of_interest\",\"raw_names\",\"obs_postint\",\"outcomes\"],\"to\":[\"obs_numeric\",\"network_binom\",\"outcomes\",\"network_smd\",\"obs_measures\",\"obs_timepoints\",\"models\",\"models\",\"model_smd\",\"obs_smd\",\"obs_smd\",\"hpp_dat\",\"data_update_date\",\"outcomes_of_interest\",\"obs_meta\",\"obs_meta\",\"raw_hpp_dat\",\"model_binom\",\"obs_wide_by_measures\",\"raw_names\",\"obs_postint\",\"obs_postint\",\"obs\",\"obs\",\"obs\",\"obs\",\"obs_binom\",\"obs_binom\"],\"arrows\":[\"to\",\"to\",\"to\",\"to\",\"to\",\"to\",\"to\",\"to\",\"to\",\"to\",\"to\",\"to\",\"to\",\"to\",\"to\",\"to\",\"to\",\"to\",\"to\",\"to\",\"to\",\"to\",\"to\",\"to\",\"to\",\"to\",\"to\",\"to\"]},\"nodesToDataframe\":true,\"edgesToDataframe\":true,\"options\":{\"width\":\"100%\",\"height\":\"100%\",\"nodes\":{\"shape\":\"dot\",\"physics\":false},\"manipulation\":{\"enabled\":false},\"edges\":{\"smooth\":{\"type\":\"cubicBezier\",\"forceDirection\":\"horizontal\"}},\"physics\":{\"stabilization\":false},\"layout\":{\"hierarchical\":{\"enabled\":true,\"direction\":\"LR\"}}},\"groups\":null,\"width\":null,\"height\":null,\"idselection\":{\"enabled\":false,\"style\":\"width: 150px; height: 26px\",\"useLabels\":true,\"main\":\"Select by id\"},\"byselection\":{\"enabled\":false,\"style\":\"width: 150px; height: 26px\",\"multiple\":false,\"hideColor\":\"rgba(200,200,200,0.5)\",\"highlight\":false},\"main\":{\"text\":\"\",\"style\":\"font-family:Georgia, Times New Roman, Times, serif;font-weight:bold;font-size:20px;text-align:center;\"},\"submain\":null,\"footer\":null,\"background\":\"rgba(0, 0, 0, 0)\",\"highlight\":{\"enabled\":false,\"hoverNearest\":false,\"degree\":1,\"algorithm\":\"all\",\"hideColor\":\"rgba(200,200,200,0.5)\",\"labelOnly\":true},\"collapse\":{\"enabled\":true,\"fit\":false,\"resetHighlight\":true,\"clusterOptions\":null,\"keepCoord\":true,\"labelSuffix\":\"(cluster)\"},\"legend\":{\"width\":0.2,\"useGroups\":false,\"position\":\"right\",\"ncol\":1,\"stepX\":100,\"stepY\":100,\"zoom\":true,\"nodes\":{\"label\":[\"Pattern\",\"Stem\"],\"shape\":[\"square\",\"dot\"],\"color\":[\"#899DA4\",\"#899DA4\"]},\"nodesToDataframe\":true}},\"evals\":[],\"jsHooks\":[]}\n\n\n\n",
      "last_modified": "2021-04-07T20:23:53+01:00"
    },
    {
      "path": "overview.html",
      "title": "overview",
      "description": "Summary information about all data for all outcomes.\n",
      "author": [],
      "date": "`r Sys.Date()`",
      "contents": "\n\nContents\noverview\nintervention class\nNumber of studies by chronic pain condition\nNumber of studies by class\nmulti-armed studies\nFrequency of comparisons\n\n\n\n\n\n\n\n\n\n\n\nAs of Wednesday 7 April 2021, the analysis currently includes 162 out of an expected 178 studies.\n\n\n\noverview\nintervention class\n\n\n\n\nhtml {\n  font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Helvetica Neue', 'Fira Sans', 'Droid Sans', Arial, sans-serif;\n}\n\n#ufbsigkbqp .gt_table {\n  display: table;\n  border-collapse: collapse;\n  margin-left: auto;\n  margin-right: auto;\n  color: #333333;\n  font-size: 16px;\n  font-weight: normal;\n  font-style: normal;\n  background-color: #f0f0f0;\n  width: auto;\n  border-top-style: solid;\n  border-top-width: 2px;\n  border-top-color: #A8A8A8;\n  border-right-style: none;\n  border-right-width: 2px;\n  border-right-color: #D3D3D3;\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #A8A8A8;\n  border-left-style: none;\n  border-left-width: 2px;\n  border-left-color: #D3D3D3;\n}\n\n#ufbsigkbqp .gt_heading {\n  background-color: #f0f0f0;\n  text-align: center;\n  border-bottom-color: #f0f0f0;\n  border-left-style: none;\n  border-left-width: 1px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 1px;\n  border-right-color: #D3D3D3;\n}\n\n#ufbsigkbqp .gt_title {\n  color: #333333;\n  font-size: 125%;\n  font-weight: initial;\n  padding-top: 4px;\n  padding-bottom: 4px;\n  border-bottom-color: #f0f0f0;\n  border-bottom-width: 0;\n}\n\n#ufbsigkbqp .gt_subtitle {\n  color: #333333;\n  font-size: 85%;\n  font-weight: initial;\n  padding-top: 0;\n  padding-bottom: 4px;\n  border-top-color: #f0f0f0;\n  border-top-width: 0;\n}\n\n#ufbsigkbqp .gt_bottom_border {\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n}\n\n#ufbsigkbqp .gt_col_headings {\n  border-top-style: solid;\n  border-top-width: 2px;\n  border-top-color: #D3D3D3;\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n  border-left-style: none;\n  border-left-width: 1px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 1px;\n  border-right-color: #D3D3D3;\n}\n\n#ufbsigkbqp .gt_col_heading {\n  color: #FFFFFF;\n  background-color: #969696;\n  font-size: 100%;\n  font-weight: normal;\n  text-transform: inherit;\n  border-left-style: none;\n  border-left-width: 1px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 1px;\n  border-right-color: #D3D3D3;\n  vertical-align: bottom;\n  padding-top: 5px;\n  padding-bottom: 6px;\n  padding-left: 5px;\n  padding-right: 5px;\n  overflow-x: hidden;\n}\n\n#ufbsigkbqp .gt_column_spanner_outer {\n  color: #FFFFFF;\n  background-color: #969696;\n  font-size: 100%;\n  font-weight: normal;\n  text-transform: inherit;\n  padding-top: 0;\n  padding-bottom: 0;\n  padding-left: 4px;\n  padding-right: 4px;\n}\n\n#ufbsigkbqp .gt_column_spanner_outer:first-child {\n  padding-left: 0;\n}\n\n#ufbsigkbqp .gt_column_spanner_outer:last-child {\n  padding-right: 0;\n}\n\n#ufbsigkbqp .gt_column_spanner {\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n  vertical-align: bottom;\n  padding-top: 5px;\n  padding-bottom: 6px;\n  overflow-x: hidden;\n  display: inline-block;\n  width: 100%;\n}\n\n#ufbsigkbqp .gt_group_heading {\n  padding: 8px;\n  color: #333333;\n  background-color: #bdbdbd;\n  font-size: 100%;\n  font-weight: initial;\n  text-transform: inherit;\n  border-top-style: solid;\n  border-top-width: 2px;\n  border-top-color: #D3D3D3;\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n  border-left-style: none;\n  border-left-width: 1px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 1px;\n  border-right-color: #D3D3D3;\n  vertical-align: middle;\n}\n\n#ufbsigkbqp .gt_empty_group_heading {\n  padding: 0.5px;\n  color: #333333;\n  background-color: #bdbdbd;\n  font-size: 100%;\n  font-weight: initial;\n  border-top-style: solid;\n  border-top-width: 2px;\n  border-top-color: #D3D3D3;\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n  vertical-align: middle;\n}\n\n#ufbsigkbqp .gt_from_md > :first-child {\n  margin-top: 0;\n}\n\n#ufbsigkbqp .gt_from_md > :last-child {\n  margin-bottom: 0;\n}\n\n#ufbsigkbqp .gt_row {\n  padding-top: 8px;\n  padding-bottom: 8px;\n  padding-left: 5px;\n  padding-right: 5px;\n  margin: 10px;\n  border-top-style: solid;\n  border-top-width: 1px;\n  border-top-color: #D3D3D3;\n  border-left-style: none;\n  border-left-width: 1px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 1px;\n  border-right-color: #D3D3D3;\n  vertical-align: middle;\n  overflow-x: hidden;\n}\n\n#ufbsigkbqp .gt_stub {\n  color: #333333;\n  background-color: #f0f0f0;\n  font-size: 100%;\n  font-weight: initial;\n  text-transform: inherit;\n  border-right-style: solid;\n  border-right-width: 2px;\n  border-right-color: #D3D3D3;\n  padding-left: 12px;\n}\n\n#ufbsigkbqp .gt_summary_row {\n  color: #333333;\n  background-color: #f0f0f0;\n  text-transform: inherit;\n  padding-top: 8px;\n  padding-bottom: 8px;\n  padding-left: 5px;\n  padding-right: 5px;\n}\n\n#ufbsigkbqp .gt_first_summary_row {\n  padding-top: 8px;\n  padding-bottom: 8px;\n  padding-left: 5px;\n  padding-right: 5px;\n  border-top-style: solid;\n  border-top-width: 2px;\n  border-top-color: #D3D3D3;\n}\n\n#ufbsigkbqp .gt_grand_summary_row {\n  color: #333333;\n  background-color: #f0f0f0;\n  text-transform: inherit;\n  padding-top: 8px;\n  padding-bottom: 8px;\n  padding-left: 5px;\n  padding-right: 5px;\n}\n\n#ufbsigkbqp .gt_first_grand_summary_row {\n  padding-top: 8px;\n  padding-bottom: 8px;\n  padding-left: 5px;\n  padding-right: 5px;\n  border-top-style: double;\n  border-top-width: 6px;\n  border-top-color: #D3D3D3;\n}\n\n#ufbsigkbqp .gt_striped {\n  background-color: rgba(128, 128, 128, 0.05);\n}\n\n#ufbsigkbqp .gt_table_body {\n  border-top-style: solid;\n  border-top-width: 2px;\n  border-top-color: #D3D3D3;\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n}\n\n#ufbsigkbqp .gt_footnotes {\n  color: #333333;\n  background-color: #f0f0f0;\n  border-bottom-style: none;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n  border-left-style: none;\n  border-left-width: 2px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 2px;\n  border-right-color: #D3D3D3;\n}\n\n#ufbsigkbqp .gt_footnote {\n  margin: 0px;\n  font-size: 90%;\n  padding: 4px;\n}\n\n#ufbsigkbqp .gt_sourcenotes {\n  color: #333333;\n  background-color: #f0f0f0;\n  border-bottom-style: none;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n  border-left-style: none;\n  border-left-width: 2px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 2px;\n  border-right-color: #D3D3D3;\n}\n\n#ufbsigkbqp .gt_sourcenote {\n  font-size: 90%;\n  padding: 4px;\n}\n\n#ufbsigkbqp .gt_left {\n  text-align: left;\n}\n\n#ufbsigkbqp .gt_center {\n  text-align: center;\n}\n\n#ufbsigkbqp .gt_right {\n  text-align: right;\n  font-variant-numeric: tabular-nums;\n}\n\n#ufbsigkbqp .gt_font_normal {\n  font-weight: normal;\n}\n\n#ufbsigkbqp .gt_font_bold {\n  font-weight: bold;\n}\n\n#ufbsigkbqp .gt_font_italic {\n  font-style: italic;\n}\n\n#ufbsigkbqp .gt_super {\n  font-size: 65%;\n}\n\n#ufbsigkbqp .gt_footnote_marks {\n  font-style: italic;\n  font-size: 65%;\n}\nintervention type\n      number of studies\n      number of antidepressants\n      antidepressants\n    SNRI\n      72\n      8\n      milnacipran; duloxetine; desvenlafaxine; pregabalin; venlafaxine; esreboxetine; cbt; education\n    TCA\n      62\n      23\n      amitriptyline; amitriptyline + fluphenazine; amitriptyline + placebo; imipramine; dothiepin; desipramine; amitriptyline + pyschotherapy; amitriptyline + support; doxepin; nortriptyline; morphine + nortriptyline; nortriptyline + cbt; nortriptyline + mgt; combination; epidural; physiotherapy + amitriptyline; physical + amitriptyline; amitriptyline + cbt; nortriptyline + morphine; desipramine + cbt; gabapentin; trimipramine; clomipramine\n    not an antidepressant\n      49\n      37\n      NA\n    SSRI\n      29\n      8\n      fluoxetine + placebo; paroxetine; citalopram; escitalopram; fluoxetine; zimelidine; sertraline; cst + sertraline\n    SARI\n      4\n      1\n      trazodone\n    NaSSA\n      3\n      1\n      mirtazapine\n    TeCA\n      2\n      2\n      maprotiline; mianserin\n    a4b2 NNR agonist\n      1\n      1\n      abt\n    Hormone\n      1\n      1\n      melatonin\n    NaRI\n      1\n      1\n      reboxetine\n    NDRI\n      1\n      1\n      bupropion\n    Reversible MAOI\n      1\n      1\n      pirlindole\n    Reversible MAOI. RIMA.\n      1\n      1\n      moclobemide\n    TCA + SSRI\n      1\n      1\n      amitriptyline + fluoxetine\n    TCA+hormone\n      1\n      1\n      melatonin\n    tetracyclic antidepressant (TeCA)\n      1\n      1\n      maprotiline\n    Tetracyclic antidepressant (TeCA)\n      1\n      1\n      mianserin\n    Tetracyclic antidepressants (TeCA)\n      1\n      1\n      maprotiline\n    Tetracylic antidepressant (TeCA)\n      1\n      1\n      maprotiline\n    \n\nNumber of studies by chronic pain condition\n\nhtml {\n  font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Helvetica Neue', 'Fira Sans', 'Droid Sans', Arial, sans-serif;\n}\n\n#gmhzeicwen .gt_table {\n  display: table;\n  border-collapse: collapse;\n  margin-left: auto;\n  margin-right: auto;\n  color: #333333;\n  font-size: 16px;\n  font-weight: normal;\n  font-style: normal;\n  background-color: #f0f0f0;\n  width: auto;\n  border-top-style: solid;\n  border-top-width: 2px;\n  border-top-color: #A8A8A8;\n  border-right-style: none;\n  border-right-width: 2px;\n  border-right-color: #D3D3D3;\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #A8A8A8;\n  border-left-style: none;\n  border-left-width: 2px;\n  border-left-color: #D3D3D3;\n}\n\n#gmhzeicwen .gt_heading {\n  background-color: #f0f0f0;\n  text-align: center;\n  border-bottom-color: #f0f0f0;\n  border-left-style: none;\n  border-left-width: 1px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 1px;\n  border-right-color: #D3D3D3;\n}\n\n#gmhzeicwen .gt_title {\n  color: #333333;\n  font-size: 125%;\n  font-weight: initial;\n  padding-top: 4px;\n  padding-bottom: 4px;\n  border-bottom-color: #f0f0f0;\n  border-bottom-width: 0;\n}\n\n#gmhzeicwen .gt_subtitle {\n  color: #333333;\n  font-size: 85%;\n  font-weight: initial;\n  padding-top: 0;\n  padding-bottom: 4px;\n  border-top-color: #f0f0f0;\n  border-top-width: 0;\n}\n\n#gmhzeicwen .gt_bottom_border {\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n}\n\n#gmhzeicwen .gt_col_headings {\n  border-top-style: solid;\n  border-top-width: 2px;\n  border-top-color: #D3D3D3;\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n  border-left-style: none;\n  border-left-width: 1px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 1px;\n  border-right-color: #D3D3D3;\n}\n\n#gmhzeicwen .gt_col_heading {\n  color: #FFFFFF;\n  background-color: #969696;\n  font-size: 100%;\n  font-weight: normal;\n  text-transform: inherit;\n  border-left-style: none;\n  border-left-width: 1px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 1px;\n  border-right-color: #D3D3D3;\n  vertical-align: bottom;\n  padding-top: 5px;\n  padding-bottom: 6px;\n  padding-left: 5px;\n  padding-right: 5px;\n  overflow-x: hidden;\n}\n\n#gmhzeicwen .gt_column_spanner_outer {\n  color: #FFFFFF;\n  background-color: #969696;\n  font-size: 100%;\n  font-weight: normal;\n  text-transform: inherit;\n  padding-top: 0;\n  padding-bottom: 0;\n  padding-left: 4px;\n  padding-right: 4px;\n}\n\n#gmhzeicwen .gt_column_spanner_outer:first-child {\n  padding-left: 0;\n}\n\n#gmhzeicwen .gt_column_spanner_outer:last-child {\n  padding-right: 0;\n}\n\n#gmhzeicwen .gt_column_spanner {\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n  vertical-align: bottom;\n  padding-top: 5px;\n  padding-bottom: 6px;\n  overflow-x: hidden;\n  display: inline-block;\n  width: 100%;\n}\n\n#gmhzeicwen .gt_group_heading {\n  padding: 8px;\n  color: #333333;\n  background-color: #bdbdbd;\n  font-size: 100%;\n  font-weight: initial;\n  text-transform: inherit;\n  border-top-style: solid;\n  border-top-width: 2px;\n  border-top-color: #D3D3D3;\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n  border-left-style: none;\n  border-left-width: 1px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 1px;\n  border-right-color: #D3D3D3;\n  vertical-align: middle;\n}\n\n#gmhzeicwen .gt_empty_group_heading {\n  padding: 0.5px;\n  color: #333333;\n  background-color: #bdbdbd;\n  font-size: 100%;\n  font-weight: initial;\n  border-top-style: solid;\n  border-top-width: 2px;\n  border-top-color: #D3D3D3;\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n  vertical-align: middle;\n}\n\n#gmhzeicwen .gt_from_md > :first-child {\n  margin-top: 0;\n}\n\n#gmhzeicwen .gt_from_md > :last-child {\n  margin-bottom: 0;\n}\n\n#gmhzeicwen .gt_row {\n  padding-top: 8px;\n  padding-bottom: 8px;\n  padding-left: 5px;\n  padding-right: 5px;\n  margin: 10px;\n  border-top-style: solid;\n  border-top-width: 1px;\n  border-top-color: #D3D3D3;\n  border-left-style: none;\n  border-left-width: 1px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 1px;\n  border-right-color: #D3D3D3;\n  vertical-align: middle;\n  overflow-x: hidden;\n}\n\n#gmhzeicwen .gt_stub {\n  color: #333333;\n  background-color: #f0f0f0;\n  font-size: 100%;\n  font-weight: initial;\n  text-transform: inherit;\n  border-right-style: solid;\n  border-right-width: 2px;\n  border-right-color: #D3D3D3;\n  padding-left: 12px;\n}\n\n#gmhzeicwen .gt_summary_row {\n  color: #333333;\n  background-color: #f0f0f0;\n  text-transform: inherit;\n  padding-top: 8px;\n  padding-bottom: 8px;\n  padding-left: 5px;\n  padding-right: 5px;\n}\n\n#gmhzeicwen .gt_first_summary_row {\n  padding-top: 8px;\n  padding-bottom: 8px;\n  padding-left: 5px;\n  padding-right: 5px;\n  border-top-style: solid;\n  border-top-width: 2px;\n  border-top-color: #D3D3D3;\n}\n\n#gmhzeicwen .gt_grand_summary_row {\n  color: #333333;\n  background-color: #f0f0f0;\n  text-transform: inherit;\n  padding-top: 8px;\n  padding-bottom: 8px;\n  padding-left: 5px;\n  padding-right: 5px;\n}\n\n#gmhzeicwen .gt_first_grand_summary_row {\n  padding-top: 8px;\n  padding-bottom: 8px;\n  padding-left: 5px;\n  padding-right: 5px;\n  border-top-style: double;\n  border-top-width: 6px;\n  border-top-color: #D3D3D3;\n}\n\n#gmhzeicwen .gt_striped {\n  background-color: rgba(128, 128, 128, 0.05);\n}\n\n#gmhzeicwen .gt_table_body {\n  border-top-style: solid;\n  border-top-width: 2px;\n  border-top-color: #D3D3D3;\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n}\n\n#gmhzeicwen .gt_footnotes {\n  color: #333333;\n  background-color: #f0f0f0;\n  border-bottom-style: none;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n  border-left-style: none;\n  border-left-width: 2px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 2px;\n  border-right-color: #D3D3D3;\n}\n\n#gmhzeicwen .gt_footnote {\n  margin: 0px;\n  font-size: 90%;\n  padding: 4px;\n}\n\n#gmhzeicwen .gt_sourcenotes {\n  color: #333333;\n  background-color: #f0f0f0;\n  border-bottom-style: none;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n  border-left-style: none;\n  border-left-width: 2px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 2px;\n  border-right-color: #D3D3D3;\n}\n\n#gmhzeicwen .gt_sourcenote {\n  font-size: 90%;\n  padding: 4px;\n}\n\n#gmhzeicwen .gt_left {\n  text-align: left;\n}\n\n#gmhzeicwen .gt_center {\n  text-align: center;\n}\n\n#gmhzeicwen .gt_right {\n  text-align: right;\n  font-variant-numeric: tabular-nums;\n}\n\n#gmhzeicwen .gt_font_normal {\n  font-weight: normal;\n}\n\n#gmhzeicwen .gt_font_bold {\n  font-weight: bold;\n}\n\n#gmhzeicwen .gt_font_italic {\n  font-style: italic;\n}\n\n#gmhzeicwen .gt_super {\n  font-size: 65%;\n}\n\n#gmhzeicwen .gt_footnote_marks {\n  font-style: italic;\n  font-size: 65%;\n}\nChronic pain condition\n      Number of studies\n      Number of interventions\n    Fibromyalgia\n      53\n      72\n    Chronic low back pain\n      8\n      15\n    Diabetic peripheral neuropathy\n      4\n      11\n    Painful diabetic neuropathy\n      4\n      11\n    Diabetic peripheral neuropathic pain\n      4\n      8\n    Knee osteoarthritis\n      4\n      6\n    Diabetic Peripheral Neuropathic Pain\n      3\n      7\n    Rheumatoid Arthritis\n      3\n      5\n    Chronic Low Back Pain\n      3\n      3\n    Non-cardiac chest pain\n      2\n      6\n    Painful polyneuropathy\n      2\n      6\n    Low back pain\n      2\n      5\n    Post-herpetic neuralgia\n      2\n      5\n    Burning Mouth Syndrome\n      2\n      4\n    Knee Osteoarthritis\n      2\n      3\n    “19 patients with painful diabetic polyneuropathy and 18 patients with painful nondiabetic polyneuropathy”\n      1\n      6\n    painful diabetic peripheral neuropathy (DPN).\n      1\n      5\n    Chronic neuropathic pain following treatment for breast cancer\n      1\n      4\n    Chronic Postherpetic Neuralgia\n      1\n      4\n    Chronic temporomandibular disorders\n      1\n      4\n    Chronic, intractable 'psychogenic' pain\n      1\n      4\n    Functional Bowel DIsorders\n      1\n      4\n    Low back pain/lumbar radiculopathy\n      1\n      4\n    Temporomandibular Joint Disorders (TMD)\n      1\n      4\n    Vulvodynia\n      1\n      4\n    Central post-stroke pain\n      1\n      3\n    Chronic pain syndromes: of the 59 randomised participants: 27 presented with low back pain, 16 with\nosteoarthritis, 8 with fibromyalgia, and 8 with rheumatoid arthritis\n      1\n      3\n    Chronic peripheral neuropathic pain\nConditions include: n(%)\nDiabetic peripheral neuropathy: 16 (31%)\nIdiopathic polyneuropathy: 15 (29%)\nPostherpetic neuralgia: 12 (23%)\nChemotherapy-induced peripheral neuropathy: 6 (12%)\nPosttraumatic neuropathy: 2 (4%)\nMyelin-associated glycoprotein neuropathy: 1 (2%)\n      1\n      3\n    Diabetic neuropathic pain\n      1\n      3\n    Diabetic polyneuropathy\n      1\n      3\n    Diabetic polyneuropathy and post-herpetic neuralgia\n      1\n      3\n    Hand osteoarthritis\n      1\n      3\n    Idiopathic pain syndrome, mainly: tension headache, burning mouth syndrome, abdominal pain and low back pain.       .     In brief, of the included 253 patients in the study byLoldrup et al. (1989) 114 had tension headache (age: 17–69 years, median 41.0 years; 64% females); 47 patients hadabdominal pain (age: 20–78 years, median 45.5 years; 70%females); 15 patients with low back pain (age: 26–68 years;median 40 years; 60% females); and 77 patients with burningmouth (age: 38–80 years; median 63 years; 92% females).\n      1\n      3\n    Irritable Bowel Syndrome, Diarrhea-predominant IBS was the most common\ncondition in each study group.\n      1\n      3\n    Neuropathic pain (post-herpetic neuralgia, diabetic polyneuropathy, traumatic plexus avulsion, peripheral nerve injury, failed back surgery syndrome, phantom pain, post-stroke pain)\n      1\n      3\n    Painful diabetic peripheral neuropathy\n      1\n      3\n    Postherpetic neuralgia\n      1\n      3\n    Severe IBS\n      1\n      3\n    Arm pain -  We included individuals with a range of clinical diagnoses involving the tendons, soft tissues and nerves of the arm, as well as those with non-specific arm symptoms related to movement (‘‘overuse strain syndrome”).\n      1\n      2\n    Atypical facial pain\n      1\n      2\n    Central neuropathic pain caused by lesion or dysfunction in the CNS.\n      1\n      2\n    Central pain in Multiple Sclerosis\n      1\n      2\n    Chemotherapy-Induced Painful Peripheral Neuropathy\n      1\n      2\n    Chronic cervical and/or lumbar spine pain\n      1\n      2\n    Chronic knee osteoarthritis\n      1\n      2\n    Chronic low back pain with a neuropathic component\n      1\n      2\n    Chronic neck pain\n      1\n      2\n    Chronic neuropathic low back pain\n      1\n      2\n    chronic pain syndromes\nfrom deafferentation and with oncological pain\nwith deafferentation component . Of the 45 patients entered into the\nstudy, 27 were affected by pain caused by tumors\nand 18 by pain from other causes.\n      1\n      2\n    Chronic pain syndromes - 13 patients were regarded as having pain syndromes of predominantly organic origin while 27 of the patients had pain syndromes of predominantly psychogenic origin.\n      1\n      2\n    Chronic pelvic pain\n\n      1\n      2\n    Chronic phantom limb pain/residual limb pain after amputation\n      1\n      2\n    Diabetic Peripheral Neuropathic Pain (DPNP)\n      1\n      2\n    Diabetic Peripheral Neuropathy\n      1\n      2\n    Fibromyalgia with insomnia\n      1\n      2\n    Functional Gastrointestinal Disorder\n      1\n      2\n    Idiopathic pain syndrome (as defined by Williams and Spitzer, 1982). Most patients had more than one symptom and majority of patients had moderate to severe pain in the head region and/or chronic pain in neck, shoulders, arms and/or back.\n      1\n      2\n    Interstitial cystitis (IC)\n      1\n      2\n    Interstitial cystitis/painful bladder syndrome (IC/PBS)\n      1\n      2\n    Irritable bowel syndrome\n      1\n      2\n    Irritable Bowel Syndrome\n      1\n      2\n    Multiple functional somatic syndromes\n      1\n      2\n    Neuropathic pain associated with Multiple Sclerosis.\n      1\n      2\n    Osteoarthritis of the hip or knee\n      1\n      2\n    Osteoarthritis of the knee\n      1\n      2\n    Pain related to Parkinson's disease\n      1\n      2\n    Painful Diabetic Neuropathy\n      1\n      2\n    Painful diabetic peripheral polyneuropathy\n      1\n      2\n    Painful peripheral diabetic neuropathy\n      1\n      2\n    Persistent somatoform pain disorder\n      1\n      2\n    Polyneuropathy\n      1\n      2\n    Primary fibrositis, fibromyalgia\n      1\n      2\n    Rheumatoid  arthritis\n      1\n      2\n    Rheumatoid arthritis\n      1\n      2\n    Rheumatoid arthritis as ≥5 body pain sites\n      1\n      2\n    Somatoform symptoms and medically unexplained symptoms\n      1\n      2\n    Somatoform, DSM-IV-TR pain disorder\n      1\n      2\n    Spinal cord injury (SCI)\n      1\n      2\n    The majority of subjects had simple, nonspecific low back pain.\nSome subjects had multifocal pain resulting from associated fibromyalgia, but, in all cases, pain in the low back\nwas the predominant complaint.\n      1\n      2\n    \n\nNumber of studies by class\n\nhtml {\n  font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Helvetica Neue', 'Fira Sans', 'Droid Sans', Arial, sans-serif;\n}\n\n#dzjcxhnnra .gt_table {\n  display: table;\n  border-collapse: collapse;\n  margin-left: auto;\n  margin-right: auto;\n  color: #333333;\n  font-size: 16px;\n  font-weight: normal;\n  font-style: normal;\n  background-color: #f0f0f0;\n  width: auto;\n  border-top-style: solid;\n  border-top-width: 2px;\n  border-top-color: #A8A8A8;\n  border-right-style: none;\n  border-right-width: 2px;\n  border-right-color: #D3D3D3;\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #A8A8A8;\n  border-left-style: none;\n  border-left-width: 2px;\n  border-left-color: #D3D3D3;\n}\n\n#dzjcxhnnra .gt_heading {\n  background-color: #f0f0f0;\n  text-align: center;\n  border-bottom-color: #f0f0f0;\n  border-left-style: none;\n  border-left-width: 1px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 1px;\n  border-right-color: #D3D3D3;\n}\n\n#dzjcxhnnra .gt_title {\n  color: #333333;\n  font-size: 125%;\n  font-weight: initial;\n  padding-top: 4px;\n  padding-bottom: 4px;\n  border-bottom-color: #f0f0f0;\n  border-bottom-width: 0;\n}\n\n#dzjcxhnnra .gt_subtitle {\n  color: #333333;\n  font-size: 85%;\n  font-weight: initial;\n  padding-top: 0;\n  padding-bottom: 4px;\n  border-top-color: #f0f0f0;\n  border-top-width: 0;\n}\n\n#dzjcxhnnra .gt_bottom_border {\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n}\n\n#dzjcxhnnra .gt_col_headings {\n  border-top-style: solid;\n  border-top-width: 2px;\n  border-top-color: #D3D3D3;\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n  border-left-style: none;\n  border-left-width: 1px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 1px;\n  border-right-color: #D3D3D3;\n}\n\n#dzjcxhnnra .gt_col_heading {\n  color: #FFFFFF;\n  background-color: #969696;\n  font-size: 100%;\n  font-weight: normal;\n  text-transform: inherit;\n  border-left-style: none;\n  border-left-width: 1px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 1px;\n  border-right-color: #D3D3D3;\n  vertical-align: bottom;\n  padding-top: 5px;\n  padding-bottom: 6px;\n  padding-left: 5px;\n  padding-right: 5px;\n  overflow-x: hidden;\n}\n\n#dzjcxhnnra .gt_column_spanner_outer {\n  color: #FFFFFF;\n  background-color: #969696;\n  font-size: 100%;\n  font-weight: normal;\n  text-transform: inherit;\n  padding-top: 0;\n  padding-bottom: 0;\n  padding-left: 4px;\n  padding-right: 4px;\n}\n\n#dzjcxhnnra .gt_column_spanner_outer:first-child {\n  padding-left: 0;\n}\n\n#dzjcxhnnra .gt_column_spanner_outer:last-child {\n  padding-right: 0;\n}\n\n#dzjcxhnnra .gt_column_spanner {\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n  vertical-align: bottom;\n  padding-top: 5px;\n  padding-bottom: 6px;\n  overflow-x: hidden;\n  display: inline-block;\n  width: 100%;\n}\n\n#dzjcxhnnra .gt_group_heading {\n  padding: 8px;\n  color: #333333;\n  background-color: #bdbdbd;\n  font-size: 100%;\n  font-weight: initial;\n  text-transform: inherit;\n  border-top-style: solid;\n  border-top-width: 2px;\n  border-top-color: #D3D3D3;\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n  border-left-style: none;\n  border-left-width: 1px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 1px;\n  border-right-color: #D3D3D3;\n  vertical-align: middle;\n}\n\n#dzjcxhnnra .gt_empty_group_heading {\n  padding: 0.5px;\n  color: #333333;\n  background-color: #bdbdbd;\n  font-size: 100%;\n  font-weight: initial;\n  border-top-style: solid;\n  border-top-width: 2px;\n  border-top-color: #D3D3D3;\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n  vertical-align: middle;\n}\n\n#dzjcxhnnra .gt_from_md > :first-child {\n  margin-top: 0;\n}\n\n#dzjcxhnnra .gt_from_md > :last-child {\n  margin-bottom: 0;\n}\n\n#dzjcxhnnra .gt_row {\n  padding-top: 8px;\n  padding-bottom: 8px;\n  padding-left: 5px;\n  padding-right: 5px;\n  margin: 10px;\n  border-top-style: solid;\n  border-top-width: 1px;\n  border-top-color: #D3D3D3;\n  border-left-style: none;\n  border-left-width: 1px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 1px;\n  border-right-color: #D3D3D3;\n  vertical-align: middle;\n  overflow-x: hidden;\n}\n\n#dzjcxhnnra .gt_stub {\n  color: #333333;\n  background-color: #f0f0f0;\n  font-size: 100%;\n  font-weight: initial;\n  text-transform: inherit;\n  border-right-style: solid;\n  border-right-width: 2px;\n  border-right-color: #D3D3D3;\n  padding-left: 12px;\n}\n\n#dzjcxhnnra .gt_summary_row {\n  color: #333333;\n  background-color: #f0f0f0;\n  text-transform: inherit;\n  padding-top: 8px;\n  padding-bottom: 8px;\n  padding-left: 5px;\n  padding-right: 5px;\n}\n\n#dzjcxhnnra .gt_first_summary_row {\n  padding-top: 8px;\n  padding-bottom: 8px;\n  padding-left: 5px;\n  padding-right: 5px;\n  border-top-style: solid;\n  border-top-width: 2px;\n  border-top-color: #D3D3D3;\n}\n\n#dzjcxhnnra .gt_grand_summary_row {\n  color: #333333;\n  background-color: #f0f0f0;\n  text-transform: inherit;\n  padding-top: 8px;\n  padding-bottom: 8px;\n  padding-left: 5px;\n  padding-right: 5px;\n}\n\n#dzjcxhnnra .gt_first_grand_summary_row {\n  padding-top: 8px;\n  padding-bottom: 8px;\n  padding-left: 5px;\n  padding-right: 5px;\n  border-top-style: double;\n  border-top-width: 6px;\n  border-top-color: #D3D3D3;\n}\n\n#dzjcxhnnra .gt_striped {\n  background-color: rgba(128, 128, 128, 0.05);\n}\n\n#dzjcxhnnra .gt_table_body {\n  border-top-style: solid;\n  border-top-width: 2px;\n  border-top-color: #D3D3D3;\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n}\n\n#dzjcxhnnra .gt_footnotes {\n  color: #333333;\n  background-color: #f0f0f0;\n  border-bottom-style: none;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n  border-left-style: none;\n  border-left-width: 2px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 2px;\n  border-right-color: #D3D3D3;\n}\n\n#dzjcxhnnra .gt_footnote {\n  margin: 0px;\n  font-size: 90%;\n  padding: 4px;\n}\n\n#dzjcxhnnra .gt_sourcenotes {\n  color: #333333;\n  background-color: #f0f0f0;\n  border-bottom-style: none;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n  border-left-style: none;\n  border-left-width: 2px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 2px;\n  border-right-color: #D3D3D3;\n}\n\n#dzjcxhnnra .gt_sourcenote {\n  font-size: 90%;\n  padding: 4px;\n}\n\n#dzjcxhnnra .gt_left {\n  text-align: left;\n}\n\n#dzjcxhnnra .gt_center {\n  text-align: center;\n}\n\n#dzjcxhnnra .gt_right {\n  text-align: right;\n  font-variant-numeric: tabular-nums;\n}\n\n#dzjcxhnnra .gt_font_normal {\n  font-weight: normal;\n}\n\n#dzjcxhnnra .gt_font_bold {\n  font-weight: bold;\n}\n\n#dzjcxhnnra .gt_font_italic {\n  font-style: italic;\n}\n\n#dzjcxhnnra .gt_super {\n  font-size: 65%;\n}\n\n#dzjcxhnnra .gt_footnote_marks {\n  font-style: italic;\n  font-size: 65%;\n}\nintervention\n      number of studies\n      number of dosages\n    Antidepressant\n    duloxetine\n      43\n      23\n    amitriptyline\n      34\n      23\n    milnacipran\n      17\n      10\n    paroxetine\n      9\n      8\n    fluoxetine\n      7\n      3\n    venlafaxine\n      7\n      9\n    imipramine\n      6\n      5\n    nortriptyline\n      6\n      4\n    citalopram\n      5\n      4\n    desipramine\n      5\n      4\n    maprotiline\n      4\n      5\n    escitalopram\n      3\n      3\n    mirtazapine\n      3\n      2\n    trazodone\n      3\n      3\n    clomipramine\n      2\n      2\n    desvenlafaxine\n      2\n      8\n    dothiepin\n      2\n      2\n    doxepin\n      2\n      2\n    esreboxetine\n      2\n      3\n    mianserin\n      2\n      2\n    sertraline\n      2\n      1\n    amitriptyline + placebo\n      1\n      1\n    bupropion\n      1\n      1\n    fluoxetine + placebo\n      1\n      1\n    moclobemide\n      1\n      1\n    pirlindole\n      1\n      1\n    reboxetine\n      1\n      1\n    trimipramine\n      1\n      1\n    zimelidine\n      1\n      1\n    Anticonvulsant\n    pregabalin\n      9\n      8\n    gabapentin\n      4\n      4\n    carbamazepine\n      3\n      3\n    lamotrigine\n      1\n      1\n    Active placebo\n    benzotropine\n      2\n      2\n    benztropine\n      1\n      1\n    diphenhydramine\n      1\n      1\n    Psychological therapy\n    cbt\n      2\n      1\n    psychotherapy\n      1\n      1\n    Neuronal nicotinic acetylcholine receptor agonist\n    abt\n      1\n      3\n    Analgesic\n    acetaminophen\n      1\n      1\n    Acupuncture\n    acupuncture\n      1\n      1\n    Exercise\n    aerobic\n      1\n      1\n    Antidepressant + NSAID\n    amitriptyline\n      1\n      1\n    Antidepressant and psychological therapy\n    amitriptyline + cbt\n      1\n      1\n    Combination of Antidepressant + Antidepressant\n    amitriptyline + fluoxetine\n      1\n      1\n    Antidepressant + Antipsychotic\n    amitriptyline + fluphenazine\n      1\n      1\n    Antidepressant + placebo\n    amitriptyline + placebo\n      1\n      1\n    Antidepressant + psychological therapy\n    amitriptyline + pyschotherapy\n      1\n      1\n    desipramine + cbt\n      1\n      1\n    nortriptyline + cbt\n      1\n      1\n    Antidepressant + clinician support\n    amitriptyline + support\n      1\n      1\n    Active placebo + psychological therapy\n    benztropine + cbt\n      1\n      1\n    placebo + cbt\n      1\n      1\n    Active placebo + disease management\n    benztropine + mgt\n      1\n      1\n    Behavioural (CBT) plus antidepressant medication\n    cbt\n      1\n      1\n    Behavioural (CBT) plus placebo (sugar pill) medication\n    cbt + placebo\n      1\n      1\n    Anticonvulsant + Antidepressant\n    combination\n      1\n      1\n    gabapentin\n      1\n      1\n    pregabalin\n      1\n      1\n    Medicinal plant\n    crocin\n      1\n      1\n    Psychological therapy + placebo\n    cst + placebo\n      1\n      1\n    Psychological therapy + antidepressant\n    cst + sertraline\n      1\n      1\n    Skeletal Muscle Relaxant\n    cyclobenzaprine\n      1\n      1\n    Antidepressant + placebo cream\n    desipramine\n      1\n      1\n    Antidepressant + topical  local anaesthetic\n    desipramine\n      1\n      1\n    Antidepressant + Ibuprofen 1800mg\n    dothiepin\n      1\n      1\n    Education\n    edu\n      1\n      1\n    Placebo (education) plus antidepressant medication\n    education\n      1\n      1\n    Epidural injection + antidepressant\n    epidural\n      1\n      1\n    Epidural injection + placebo\n    epidural\n      1\n      1\n    Antidepressant + Hormone\n    fluoxetine\n      1\n      2\n    Antidepressant + Placebo\n    fluoxetine + placebo\n      1\n      1\n    Antipsychotic\n    fluphenazine\n      1\n      1\n    Active Placebo\n    glycopyrrolate\n      1\n      1\n    Placebo tablet + topical  local anaesthetic\n    lidocaine\n      1\n      1\n    Benzodiazepine\n    lorazepam\n      1\n      1\n    Combination of hormone and antidepressant\n    melatonin\n      1\n      1\n    Hormone\n    melatonin\n      1\n      1\n    Hormone + Placebo\n    melatonin\n      1\n      1\n    Opioid\n    morphine\n      1\n      1\n    Painkiller\n    morphine\n      1\n      1\n    pregabalin\n      1\n      1\n    Combination opioid and antidepressant\n    morphine + nortriptyline\n      1\n      1\n    Synthetic cannabinoid\n    nabilone\n      1\n      1\n    Neurofeedback\n    neurofeedback\n      1\n      1\n    Antidepressant + disease management\n    nortriptyline + mgt\n      1\n      1\n    Combination painkiller and antidepressant\n    nortriptyline + morphine\n      1\n      1\n    Active comparator\n    panax\n      1\n      1\n    saffron\n      1\n      1\n    Cardiovascular fitness training\n    physical\n      1\n      1\n    Cardiovascular fitness training and amitriptyline\n    physical + amitriptyline\n      1\n      1\n    Physiotherapy and antidepressant\n    physiotherapy + amitriptyline\n      1\n      1\n    Placebo + cognitive behavioural therapy\n    placebo + cbt\n      1\n      1\n    Placebo\n    placebo + placebo\n      1\n      1\n    Placebo + psychological therapy\n    placebo + psychotherapy\n      1\n      1\n    Placebo + clinician support\n    placebo + support\n      1\n      1\n    Antidepressant + anticonvulsant\n    trazodone\n      1\n      1\n    Antidepressant + Anticonvulsant\n    trazodone\n      1\n      1\n    Usual care\n    usual\n      1\n      1\n    \n\nmulti-armed studies\n\nhtml {\n  font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Helvetica Neue', 'Fira Sans', 'Droid Sans', Arial, sans-serif;\n}\n\n#rjyznlnund .gt_table {\n  display: table;\n  border-collapse: collapse;\n  margin-left: auto;\n  margin-right: auto;\n  color: #333333;\n  font-size: 16px;\n  font-weight: normal;\n  font-style: normal;\n  background-color: #f0f0f0;\n  width: auto;\n  border-top-style: solid;\n  border-top-width: 2px;\n  border-top-color: #A8A8A8;\n  border-right-style: none;\n  border-right-width: 2px;\n  border-right-color: #D3D3D3;\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #A8A8A8;\n  border-left-style: none;\n  border-left-width: 2px;\n  border-left-color: #D3D3D3;\n}\n\n#rjyznlnund .gt_heading {\n  background-color: #f0f0f0;\n  text-align: center;\n  border-bottom-color: #f0f0f0;\n  border-left-style: none;\n  border-left-width: 1px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 1px;\n  border-right-color: #D3D3D3;\n}\n\n#rjyznlnund .gt_title {\n  color: #333333;\n  font-size: 125%;\n  font-weight: initial;\n  padding-top: 4px;\n  padding-bottom: 4px;\n  border-bottom-color: #f0f0f0;\n  border-bottom-width: 0;\n}\n\n#rjyznlnund .gt_subtitle {\n  color: #333333;\n  font-size: 85%;\n  font-weight: initial;\n  padding-top: 0;\n  padding-bottom: 4px;\n  border-top-color: #f0f0f0;\n  border-top-width: 0;\n}\n\n#rjyznlnund .gt_bottom_border {\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n}\n\n#rjyznlnund .gt_col_headings {\n  border-top-style: solid;\n  border-top-width: 2px;\n  border-top-color: #D3D3D3;\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n  border-left-style: none;\n  border-left-width: 1px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 1px;\n  border-right-color: #D3D3D3;\n}\n\n#rjyznlnund .gt_col_heading {\n  color: #FFFFFF;\n  background-color: #969696;\n  font-size: 100%;\n  font-weight: normal;\n  text-transform: inherit;\n  border-left-style: none;\n  border-left-width: 1px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 1px;\n  border-right-color: #D3D3D3;\n  vertical-align: bottom;\n  padding-top: 5px;\n  padding-bottom: 6px;\n  padding-left: 5px;\n  padding-right: 5px;\n  overflow-x: hidden;\n}\n\n#rjyznlnund .gt_column_spanner_outer {\n  color: #FFFFFF;\n  background-color: #969696;\n  font-size: 100%;\n  font-weight: normal;\n  text-transform: inherit;\n  padding-top: 0;\n  padding-bottom: 0;\n  padding-left: 4px;\n  padding-right: 4px;\n}\n\n#rjyznlnund .gt_column_spanner_outer:first-child {\n  padding-left: 0;\n}\n\n#rjyznlnund .gt_column_spanner_outer:last-child {\n  padding-right: 0;\n}\n\n#rjyznlnund .gt_column_spanner {\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n  vertical-align: bottom;\n  padding-top: 5px;\n  padding-bottom: 6px;\n  overflow-x: hidden;\n  display: inline-block;\n  width: 100%;\n}\n\n#rjyznlnund .gt_group_heading {\n  padding: 8px;\n  color: #333333;\n  background-color: #bdbdbd;\n  font-size: 100%;\n  font-weight: initial;\n  text-transform: inherit;\n  border-top-style: solid;\n  border-top-width: 2px;\n  border-top-color: #D3D3D3;\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n  border-left-style: none;\n  border-left-width: 1px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 1px;\n  border-right-color: #D3D3D3;\n  vertical-align: middle;\n}\n\n#rjyznlnund .gt_empty_group_heading {\n  padding: 0.5px;\n  color: #333333;\n  background-color: #bdbdbd;\n  font-size: 100%;\n  font-weight: initial;\n  border-top-style: solid;\n  border-top-width: 2px;\n  border-top-color: #D3D3D3;\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n  vertical-align: middle;\n}\n\n#rjyznlnund .gt_from_md > :first-child {\n  margin-top: 0;\n}\n\n#rjyznlnund .gt_from_md > :last-child {\n  margin-bottom: 0;\n}\n\n#rjyznlnund .gt_row {\n  padding-top: 8px;\n  padding-bottom: 8px;\n  padding-left: 5px;\n  padding-right: 5px;\n  margin: 10px;\n  border-top-style: solid;\n  border-top-width: 1px;\n  border-top-color: #D3D3D3;\n  border-left-style: none;\n  border-left-width: 1px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 1px;\n  border-right-color: #D3D3D3;\n  vertical-align: middle;\n  overflow-x: hidden;\n}\n\n#rjyznlnund .gt_stub {\n  color: #333333;\n  background-color: #f0f0f0;\n  font-size: 100%;\n  font-weight: initial;\n  text-transform: inherit;\n  border-right-style: solid;\n  border-right-width: 2px;\n  border-right-color: #D3D3D3;\n  padding-left: 12px;\n}\n\n#rjyznlnund .gt_summary_row {\n  color: #333333;\n  background-color: #f0f0f0;\n  text-transform: inherit;\n  padding-top: 8px;\n  padding-bottom: 8px;\n  padding-left: 5px;\n  padding-right: 5px;\n}\n\n#rjyznlnund .gt_first_summary_row {\n  padding-top: 8px;\n  padding-bottom: 8px;\n  padding-left: 5px;\n  padding-right: 5px;\n  border-top-style: solid;\n  border-top-width: 2px;\n  border-top-color: #D3D3D3;\n}\n\n#rjyznlnund .gt_grand_summary_row {\n  color: #333333;\n  background-color: #f0f0f0;\n  text-transform: inherit;\n  padding-top: 8px;\n  padding-bottom: 8px;\n  padding-left: 5px;\n  padding-right: 5px;\n}\n\n#rjyznlnund .gt_first_grand_summary_row {\n  padding-top: 8px;\n  padding-bottom: 8px;\n  padding-left: 5px;\n  padding-right: 5px;\n  border-top-style: double;\n  border-top-width: 6px;\n  border-top-color: #D3D3D3;\n}\n\n#rjyznlnund .gt_striped {\n  background-color: rgba(128, 128, 128, 0.05);\n}\n\n#rjyznlnund .gt_table_body {\n  border-top-style: solid;\n  border-top-width: 2px;\n  border-top-color: #D3D3D3;\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n}\n\n#rjyznlnund .gt_footnotes {\n  color: #333333;\n  background-color: #f0f0f0;\n  border-bottom-style: none;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n  border-left-style: none;\n  border-left-width: 2px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 2px;\n  border-right-color: #D3D3D3;\n}\n\n#rjyznlnund .gt_footnote {\n  margin: 0px;\n  font-size: 90%;\n  padding: 4px;\n}\n\n#rjyznlnund .gt_sourcenotes {\n  color: #333333;\n  background-color: #f0f0f0;\n  border-bottom-style: none;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n  border-left-style: none;\n  border-left-width: 2px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 2px;\n  border-right-color: #D3D3D3;\n}\n\n#rjyznlnund .gt_sourcenote {\n  font-size: 90%;\n  padding: 4px;\n}\n\n#rjyznlnund .gt_left {\n  text-align: left;\n}\n\n#rjyznlnund .gt_center {\n  text-align: center;\n}\n\n#rjyznlnund .gt_right {\n  text-align: right;\n  font-variant-numeric: tabular-nums;\n}\n\n#rjyznlnund .gt_font_normal {\n  font-weight: normal;\n}\n\n#rjyznlnund .gt_font_bold {\n  font-weight: bold;\n}\n\n#rjyznlnund .gt_font_italic {\n  font-style: italic;\n}\n\n#rjyznlnund .gt_super {\n  font-size: 65%;\n}\n\n#rjyznlnund .gt_footnote_marks {\n  font-style: italic;\n  font-size: 65%;\n}\nstudy\n      number of interventions\n      interventions\n    Functional Bowel Disorder symptoms\n    Drossman 2003\n      4\n      placebo; desipramine; cbt; edu\n    Pain\n    Goldenberg 1986\n      4\n      amitriptyline; placebo; amitriptyline + placebo; placebo + placebo\n    Gould 2020\n      4\n      placebo; desipramine; placebo + cbt; desipramine + cbt\n    Graff-Radford 2000\n      4\n      amitriptyline; amitriptyline + fluphenazine; fluphenazine; glycopyrrolate\n    Holbech 2015\n      4\n      placebo; pregabalin; imipramine; combination\n    Khoromi 2007\n      4\n      benzotropine; morphine; nortriptyline; morphine + nortriptyline\n    Nct 2003\n      4\n      benztropine + cbt; nortriptyline + cbt; benztropine + mgt; nortriptyline + mgt\n    Pilowsky 1990\n      4\n      amitriptyline + pyschotherapy; amitriptyline + support; placebo + psychotherapy; placebo + support\n    Atkinson 1999\n      3\n      maprotiline; paroxetine; diphenhydramine\n    Enteshari-Moghaddam 2019\n      3\n      acetaminophen; duloxetine; gabapentin\n    Foster 2010 | 1\n      3\n      placebo; lidocaine; desipramine; desipramine\n    Gilron 2015\n      3\n      morphine; nortriptyline; nortriptyline + morphine\n    Gilron 2016\n      3\n      placebo; pregabalin; duloxetine; pregabalin\n    Hannonen 1998\n      3\n      moclobemide; amitriptyline; placebo\n    Leijon 1989\n      3\n      placebo; amitriptyline; carbamazepine\n    Max 1988\n      3\n      placebo; amitriptyline; lorazepam\n    Rani 1996\n      3\n      placebo; fluoxetine; amitriptyline\n    Razazian 2014\n      3\n      carbamazepine; pregabalin; venlafaxine\n    Rowbotham 2005\n      3\n      desipramine; amitriptyline; fluoxetine\n    Rowbotham 2012\n      3\n      placebo; duloxetine; abt; abt; abt\n    Sencan 2004\n      3\n      aerobic; paroxetine; placebo\n    Sindrup 1990\n      3\n      placebo; paroxetine; imipramine\n    Sindrup 2003\n      3\n      placebo; venlafaxine; imipramine\n    Sofat 2016\n      3\n      placebo; pregabalin; duloxetine\n    Spinhoven 2010\n      3\n      placebo; paroxetine; cbt\n    Vrethem 1997\n      3\n      amitriptyline; amitriptyline; maprotiline; maprotiline; placebo; placebo\n    Pain, depression, quality of life and sleep\n    Calderon 2011\n      4\n      placebo; placebo + cbt; amitriptyline; amitriptyline + cbt\n    Pain, mood/anxiety and physical disability\n    Keefe 2011\n      4\n      placebo; sertraline; cst + placebo; cst + sertraline\n    Pain, tender points\n    Goldenberg 1996\n      4\n      placebo; amitriptyline + placebo; fluoxetine + placebo; amitriptyline + fluoxetine\n    Fibromyalgia symptoms\n    Braz 2013\n      3\n      placebo; amitriptyline; panax\n    Heymann 2001\n      3\n      amitriptyline; nortriptyline; placebo\n    Hussain 2011\n      3\n      melatonin; fluoxetine + placebo; fluoxetine; fluoxetine\n    IBS symptoms\n    Talley 2008\n      3\n      placebo; imipramine; citalopram\n    Mood and pain\n    Loldrup 1989\n      3\n      placebo; clomipramine; mianserin\n    Pain (pressure point)\n    Isomeri 1993\n      3\n      physiotherapy + amitriptyline; physical; physical + amitriptyline\n    Pain and fibromyalgia symptoms\n    Carette 1994\n      3\n      placebo; amitriptyline; cyclobenzaprine\n    Pain and HRQoL\n    Creed 2003\n      3\n      psychotherapy; paroxetine; usual\n    Pain and physical function\n    Ang 2013\n      3\n      cbt + placebo; cbt; education\n    Pain intensity\n    Nct 2006\n      3\n      pregabalin; amitriptyline; duloxetine\n    \n\nFrequency of comparisons\n\n\n\n",
      "last_modified": "2021-04-07T20:15:08+01:00"
    }
  ],
  "collections": []
}
